Analyst Jonathan Wolleben of JMP Securities reiterated a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report), with a price target ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) has been given an average rating of “Moderate Buy” by the thirteen ratings firms that are presently covering the stock, Marketbeat.com ...

Bank of America Securities analyst Jason Zemansky maintained a Sell rating on Madrigal Pharmaceuticals (MDGL – Research Report) today and set a ...

Madrigal Pharmaceuticals' strong launch is confirmed with impressive sales in Q1 and Q2. Learn why MDGL stock could benefit ...

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced that it will present at the 43rd Annual J.P. Morgan Healthcare ...

Madrigal Pharma has become the first drugmaker to claim FDA approval for a drug to treat metabolic dysfunction-associated steatohepatitis (MASH), an elusive target that has seen many other ...

Madrigal said that all patients enrolled in MAESTRO-NASH - which include up to 2,000 in total - are continuing on therapy after the initial 52-week treatment period.

Behind every name for a product or drug is someone writing hundreds of possible names. Lieba Golden-Koulendros made a career ...

Now, Pfizer and the trade group the Pharmaceutical Research and Manufacturers of America (PhRMA) rank among the organizations that have helped Trump raise a record-setting $150 million in pledges ...

Healthcare environments require effective decontamination procedures. These areas differ in layout, heating, ventilation, air conditioning (HVAC), engineering controls, and room classification ...

COPENHAGEN, Denmark, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in the 43rd Annual J.P. Morgan Healthcare ...